Clinical Trial

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Study acronym: NYMC207
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-03-25; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2021-08-04
Trial Details
NCT Number NCT04323748
Lead Sponsor New York Medical College
Conditions Immune Thrombocytopenic Purpura
Enrollment 20 participants
Start Date 2021-02-24
Primary Completion 2026-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-15